Physician profile
Ola E Eisa
NPI 1184806135
$975.24
in general payments reported to CMS, 2019-2025
16 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2021: $185 · 2022: $276 · 2023: $142 · 2024: $122 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $227.12 | 2019-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $162.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $100.87 | 2019-2024 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $73.46 | 2021 | |
| Abbvie INC. | $62.41 | 2021 | |
| Pfizer INC. | $61.83 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $47.26 | 2019-2025 | Enflonsia, Rotateq, Capvaxive |
| Glaxosmithkline, LLC. | $41.86 | 2022-2024 | Arexvy |
| Daiichi Sankyo INC. | $41.17 | 2025 | Injectafer |
| Lilly USA, LLC | $31.11 | 2024 | Mounjaro |
| Exact Sciences Corporation | $30.17 | 2023 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $27.17 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Kowa Pharmaceuticals America, INC. | $18.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.16 | 2022 | |
| Abbott Laboratories | $16.79 | 2024 | Freestyle Libre 3 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ola Eisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.